Psyence Biomedical Ltd. (PBM)

NASDAQ: PBM · Real-Time Price · USD

4.210

-0.100 (-2.32%)

Aug 28, 2026, 4:00 PM EDT - Market closed

Psyence Biomedical Financials Overview

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Income	-6.24	-6.24	-3.66	-2.75	-3.23	-1.86
Net Income	-6.94	-6.94	1.01	-51.16	-3.21	-1.86
Earnings Per Share	-12.56	-12.56	32.76	-	-	-
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	7.44	7.44	6.14	0.73	1.33	1.76
Total Debt	-	-	-	10.45	-	-
Net Cash (Debt)	7.44	7.44	6.14	-9.71	1.33	1.76
Net Cash Growth	21.35%	21.35%	-	-	-23.97%	-
Net Cash Per Share	13.48	13.48	198.63	-	-	-

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-8.14	-8.14	-3.73	-2.95	-1.59	-1.4
Capital Expenditures	-0	-0	-0.01	-0.01	-	-
Free Cash Flow	-8.14	-8.14	-3.74	-2.95	-1.59	-1.4
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	-	-	2.69	-	-	-